ARHGAP31

Across TCGA pan-cancer cohorts, ARHGAP31 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGAP31 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARHGAP31 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGAP31 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where ARHGAP31 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.768	0.396	.001	24	view →
LSCC	DFS	Tertile	II,III,IV	0.585	0.949	.010	13	view →
PDAC	OS	Tertile	IV	0.231	0.905	.024	3	view →
LUAD	DFS	Median	III,IV	0.542	0.938	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARHGAP31–CCRCC (DFS)

Open the CCRCC breakdown →